On the same budget, this 5.0L LS V8 is already on par with its Coyote rival, but there's still some power left to be unlocked ...

Coyote who? Look, I love late-model engine swaps as much as the next guy, but making more horsepower isn’t the reason to make the swap. Sometimes, it’s better to keep things simple. Affordable.

Shares of Caterpillar, the maker of mining and construction machinery, are up more than 30% since year-end, making it the biggest contributor to the Dow Jones Industrial Average. WSJ’s Jonathan Weil ...

Daud Gonzalez is a lifelong car enthusiast and automotive writer with a specialty in modified and race-ready rides. He spends most of his time modifying his cars and ruining them in the process. He is ...

Daud Gonzalez is a lifelong car enthusiast and automotive writer with a specialty in modified and race-ready rides. He spends most of his time modifying his cars and ruining them in the process. He is ...

Squarespace wants you to build a website with AI. Its Blueprint AI Builder feature began life as a guided website design system in 2023, but, like many things these days, it was revamped with ...

This 1960 Chevrolet Corvette C1 on Exotic Car Trader is stunningly remastered, and with a LS3 V8 Engine giving bite to its bark. The C1 Corvette is one of the most iconic Corvettes there is, by simple ...

Join me as I tour BluePrint Engines in Nebraska, the birthplace of the MONSTER 540 engine. The video features a dyno pull with a powerful 427LS, reaching 6200 RPM. #BluePrintEngines #Monster540 ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. For Bryan Johnson, balancing profit and prophet isn't easy. The biotech entrepreneur told Wired's ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Sanofi said Monday it plans ...

Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.” Sanofi has struck a ...